c2n Diagnostics partners with Mediford for Precivity™ Alzheimer’s Blood Test Expansion in Japan
C2N Diagnostics has partnered with Mediford Corporation, a subsidiary of PHC Holdings, to enhance access to its clinical research...
Biktarvy® Label Update: Hopeful News for Pregnant Adults with HIV
The U.S. Food and Drug Administration (FDA) has approved an updated label for Biktarvy, extending its safety and efficacy...
FDA Approves Pfizer’s Gene Therapy Treatment for Hemophilia B
Pfizer’s BEQVEZ, a one-time gene therapy, has received FDA approval for treating adults with moderate to severe hemophilia B....
Tivdak’s Full FDA Approval: A Triumphant Victory for Metastatic Cervical Cancer Treatment
The U.S. Food and Drug Administration (FDA) has granted full approval to TIVDAK (tisotumab vedotin-tftv) for the treatment of...
Merck’s V116 Vaccine: A Revolutionary Breakthrough for Adult Pneumococcal Protection
A Phase 3 trial (STRIDE-10) evaluated V116, a 21-valent pneumococcal conjugate vaccine, in adults over 50. The study compared...
Landmark Nature Paper Unveils Groundbreaking Covalent Inhibitor for Rare Disease
Vividion Therapeutics, a biopharmaceutical company, has made a significant discovery in the development of novel cancer and immune disorder...
Exgenesis Bio: Positive Phase 1/2 Clinical Trial Data for EXG001-307 Gene Therapy for Spinal Muscular Atrophy
Exegenesis Bio, a leading genetic medicines company, unveiled encouraging clinical efficacy and safety results for their EXG001-307 gene therapy...
Incyte’s Acquisition: Unlocking a Promising Pipeline of Groundbreaking Medicines
Incyte, a renowned biopharmaceutical company, has acquired Escient Pharmaceuticals, a pioneer in developing small molecule therapeutics for immune disorders....
Exciting New Clinical Trial Results for Duchenne Muscular Dystrophy
The international gene therapy trial for Duchenne Muscular Dystrophy (DMD) using GNT0004 has unveiled promising findings at the Myology...
Medpace First Quarter 2024: Strong Financial Gains
Medpace Holdings reported a significant financial performance for the first quarter of 2024. Revenue soared by 17.7% to $511...